[Market Focus] AimedBio Shares Rally on Highlighted 3 Trillion Won Technology Transfer Deals Ahead of Samsung Group Investment and IPO

[Market Focus] AimedBio Shares Surge on Highlighted 3 Trillion Won Technology Transfer Deals Ahead of Samsung Group Investment and IPO

AimedBio's stock price is on the rise. This appears to reflect expectations for strong performance, following investment from Samsung Group and technology transfer agreements worth 3 trillion won even before its public listing.

As of 10:09 a.m. on December 17, AimedBio's share price stood at 76,400 won, up 5.52% from the previous day. Since debuting on the KOSDAQ market at 44,000 won on December 4, the stock has surged by 73.6%.

Founded in 2018 after being spun off from Samsung Medical Center, AimedBio is developing antibody-drug conjugate (ADC)-based anticancer drugs. ADCs are a technology that delivers anticancer agents directly to target cancer cells through antigen-antibody reactions, maximizing therapeutic effects and reducing side effects compared to conventional chemotherapy.

In 2023, AimedBio became the first Korean company to receive investment from the Samsung Life Science Fund, jointly established by Samsung C&T, Samsung Biologics, and Samsung Bioepis. Last year, the company signed a large-scale technology transfer agreement with US-based Biohaven for 'AMB302.' In October this year, it entered into a technology transfer agreement worth up to 1.4 trillion won with Germany's Boehringer Ingelheim. Before its IPO, AimedBio secured technology transfer and joint development agreements totaling over 3 trillion won.

This content was produced with the assistance of AI translation services.